Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (22)

« Back to Publications

Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.

Hou MM. et al, (2025), Nat Commun, 16

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Silk SE. et al, (2024), Lancet Infect Dis, 24, 1105 - 1117

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

Silk SE. et al, (2023), Med, 4, 668 - 686.e7

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.

Hou MM. et al, (2023), Sci Transl Med, 15

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics.

Salkeld J. et al, (2022), Front Immunol, 13

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly.

Minassian AM. et al, (2021), JCI Insight, 6

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Minassian AM. et al, (2021), Med, 2, 701 - 719.e19

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Ewer KJ. et al, (2021), Nat Med, 27

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M. et al, (2021), Lancet, 397, 99 - 111

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Folegatti PM. et al, (2020), Lancet, 396, 467 - 478

DEMONSTRATION OF A BLOOD-STAGE CONTROLLED HUMAN MALARIA INFECTION MODEL FOR PLASMODIUM VIVAX VACCINE EFFICACY TESTING

Minassian AM. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 133 - 134

Load More